186 related articles for article (PubMed ID: 28018113)
41. CACYBP Enhances Cytoplasmic Retention of P27
Lian YF; Huang YL; Zhang YJ; Chen DM; Wang JL; Wei H; Bi YH; Jiang ZW; Li P; Chen MS; Huang YH
Theranostics; 2019; 9(26):8392-8408. PubMed ID: 31754404
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
43. circZFR promotes cell proliferation and migration by regulating miR-511/AKT1 axis in hepatocellular carcinoma.
Yang X; Liu L; Zou H; Zheng YW; Wang KP
Dig Liver Dis; 2019 Oct; 51(10):1446-1455. PubMed ID: 31147216
[TBL] [Abstract][Full Text] [Related]
44. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
45. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
46. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
47. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
Li D; Zhang Y; Zhang H; Zhan C; Li X; Ba T; Qiu Z; E F; Lv G; Zou C; Wang C; Si L; Zou C; Li Q; Gao X
J Exp Clin Cancer Res; 2018 Mar; 37(1):46. PubMed ID: 29506532
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.
Dong X; Wang F; Xue Y; Lin Z; Song W; Yang N; Li Q
Int J Mol Med; 2019 Mar; 43(3):1417-1429. PubMed ID: 30664155
[TBL] [Abstract][Full Text] [Related]
49. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
50. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
[TBL] [Abstract][Full Text] [Related]
51. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
Xie L; Li M; Liu D; Wang X; Wang P; Dai H; Yang W; Liu W; Hu X; Zhao M
Molecules; 2019 Jan; 24(3):. PubMed ID: 30678274
[TBL] [Abstract][Full Text] [Related]
52. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
53. lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway.
Pan W; Li W; Zhao J; Huang Z; Zhao J; Chen S; Wang C; Xue Y; Huang F; Fang Q; Wang J; Brand D; Zheng SG
Mol Oncol; 2019 Oct; 13(10):2246-2258. PubMed ID: 31368655
[TBL] [Abstract][Full Text] [Related]
54. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
55. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
56. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
57. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
58. A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival.
Liu F; Zhu C; Huang X; Cai J; Wang H; Wang X; He S; Liu C; Yang X; Zhang Y; Zhang T
Pathol Res Pract; 2014 Dec; 210(12):885-92. PubMed ID: 25169131
[TBL] [Abstract][Full Text] [Related]
59. Abnormal expression and mechanism of miR-330-3p/BTG1 axis in hepatocellular carcinoma.
Zhao X; Chen GQ; Cao GM
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6888-6898. PubMed ID: 31486488
[TBL] [Abstract][Full Text] [Related]
60. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
